Novartis Plans Fast Entresto Launch Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.
You may also be interested in...
Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
ICER Hands CMS A Drug Price Negotiation Cheat Sheet
The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.